Biotech · Private company
BeiGene
Track this companyFree. Adds BeiGene to your Dealase workspace and tells you when its record changes.
Clinical trials2516 recruiting or active
Pipeline programs40From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline40
- BendamustinePhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- OciperlimabPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- TislelizumabPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- ZanubrutinibPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- AlcestobartPhase 2 · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- AlcestobartPhase 2 · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-inClinicalTrials.gov · fetched Nov 12, 2026
- Bevacizumab or Bevacizumab biosimilarPhase 2 · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- BGB-A425Phase 2 · Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- BGB-A445Phase 2 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 2 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CisplatinPhase 2 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Fluoropyrimidine (FP)Phase 2 · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- LBL-007Phase 2 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- LBL-007Phase 2 · Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- pemetrexedPhase 2 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- SurzebiclimabPhase 2 · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-inClinicalTrials.gov · fetched Nov 12, 2026
- TislelizumabPhase 2 · Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- TislelizumabPhase 2 · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- TislelizumabPhase 2 · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-inClinicalTrials.gov · fetched Nov 12, 2026
- BG-68501Phase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- BGB-15025Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- BGB-16673Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- BGB-43395Phase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- BGB-A3055Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- BGB-B3227Phase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- ChemotherapyPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- ChemotherapyPhase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- CisplatinPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ItraconazolePhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- OxaliplatinPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PhenytoinPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- TislelizumabPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- TislelizumabPhase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- ZanubrutinibWaldenstrom MacroglobulinemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant ChemotherapyPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 18, 2025ClinicalTrials.gov NCT07136077 · fetched Nov 12, 2026
- BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaPHASE2 · RECRUITING · started Apr 22, 2025ClinicalTrials.gov NCT06854003 · fetched Nov 12, 2026
- Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS LymphomaPHASE1 · RECRUITING · started Apr 17, 2025ClinicalTrials.gov NCT06730542 · fetched Nov 12, 2026
- Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy ParticipantsPHASE1 · COMPLETED · started Apr 3, 2025ClinicalTrials.gov NCT06906809 · fetched Nov 12, 2026
- Epco, Zanu, Ritux for R/R FL or MZLPHASE2 · RECRUITING · started Jan 21, 2025ClinicalTrials.gov NCT06563596 · fetched Nov 12, 2026
- A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid TumorsPHASE1 · TERMINATED · started Sep 11, 2024ClinicalTrials.gov NCT06540066 · fetched Nov 12, 2026
- Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) LymphomasPHASE2 · RECRUITING · started Apr 25, 2024ClinicalTrials.gov NCT05681195 · fetched Nov 12, 2026
- A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Mar 11, 2024ClinicalTrials.gov NCT06257264 · fetched Nov 12, 2026
- A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas CancerPHASE2 · RECRUITING · started Nov 8, 2023ClinicalTrials.gov NCT05604560 · fetched Nov 12, 2026
- BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid TumorsPHASE1 · TERMINATED · started Aug 21, 2023ClinicalTrials.gov NCT05935098 · fetched Nov 12, 2026
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell CarcinomaPHASE2 · COMPLETED · started Aug 2, 2023ClinicalTrials.gov NCT05909904 · fetched Nov 12, 2026
- Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based ObinutuzumabPHASE2 · ACTIVE_NOT_RECRUITING · started May 8, 2023ClinicalTrials.gov NCT05650723 · fetched Nov 12, 2026
- Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström MacroglobulinemiaRECRUITING · started Mar 3, 2023ClinicalTrials.gov NCT05640102 · fetched Nov 12, 2026
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung CancerPHASE2 · COMPLETED · started Feb 10, 2023ClinicalTrials.gov NCT05635708 · fetched Nov 12, 2026
- A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal CancerPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jan 29, 2023ClinicalTrials.gov NCT05609370 · fetched Nov 12, 2026
- Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)PHASE1_PHASE2 · RECRUITING · started Aug 11, 2022ClinicalTrials.gov NCT05431270 · fetched Nov 12, 2026
- Zanubrutinib and Venetoclax in CLL (ZANU-VEN)PHASE2 · RECRUITING · started Feb 18, 2022ClinicalTrials.gov NCT05168930 · fetched Nov 12, 2026
- First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 25, 2022ClinicalTrials.gov NCT05189457 · fetched Nov 12, 2026
- A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerPHASE3 · TERMINATED · started May 24, 2021ClinicalTrials.gov NCT04746924 · fetched Nov 12, 2026
- BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid TumorsPHASE1 · COMPLETED · started Mar 4, 2021ClinicalTrials.gov NCT04649385 · fetched Nov 12, 2026
- Study of Pamiparib in Newly Diagnosed and rGBMEARLY_PHASE1 · COMPLETED · started Jan 11, 2021ClinicalTrials.gov NCT04614909 · fetched Nov 12, 2026
- Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerPHASE1 · RECRUITING · started Mar 4, 2020ClinicalTrials.gov NCT04221542 · fetched Nov 12, 2026
- BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV GliomasPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 3, 2019ClinicalTrials.gov NCT03749187 · fetched Nov 12, 2026
- Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid TumorsPHASE1_PHASE2 · COMPLETED · started Nov 13, 2018ClinicalTrials.gov NCT03744468 · fetched Nov 12, 2026
- A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLLPHASE3 · ACTIVE_NOT_RECRUITING · started Oct 31, 2017ClinicalTrials.gov NCT03336333 · fetched Nov 12, 2026